GO:0051346 negative regulation of hydrolase activity: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051346 (negative regulation of hydrolase activity) describes any process that stops or reduces the rate of hydrolase-catalyzed bond hydrolysis, a central control node in signaling, immunity, and metabolism.
• Hydrolase inhibition is achieved by dedicated inhibitors, phosphatases, GTPase-activating proteins, and proteolytic zymogen control, as shown for VHR-mediated ERK dephosphorylation and Ras-GAP-accelerated GTP hydrolysis.
• Dysregulated hydrolase inhibition contributes to cancer, neuroinflammation, and cardiovascular pathology, including A20 loss in NF-kB-driven malignancy and soluble epoxide hydrolase effects in astrocytes.
• Key experimental genes include DUSP3/VHR, TNFAIP3/A20, RASA1, EPHX2, and MBTPS1, each amenable to CRISPR knockout, point-mutation, knock-in, or overexpression modeling.
• CRISPR-based cell models combined with phospho-proteomics, activity assays, and transcriptomics allow causal dissection of hydrolase inhibitory circuits.
• EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models and CRISPR library screening/bioinformatics to accelerate GO:0051346 research.
Description
GO:0051346, negative regulation of hydrolase activity, is a biological process Gene Ontology term defined as any process that stops or reduces the rate of hydrolase activity, the catalysis of the hydrolysis of various bonds. Hydrolases cleave covalent bonds using water and include phosphatases, GTPases, proteases, and epoxide hydrolases; their negative regulation therefore acts as a molecular brake on diverse signaling and metabolic pathways. Because hydrolysis is irreversible under physiological conditions, cells rely on inhibitors, competing substrates, post-translational modifications, and scaffold proteins to tune hydrolase output precisely. This term matters because loss of hydrolase inhibition is a recurring theme in human disease. For example, A20 (TNFAIP3) negatively regulates canonical NF-kB signaling by restricting upstream hydrolase-dependent events, and its inactivation promotes constitutive inflammatory signaling. Similarly, the phosphatase VHR (DUSP3) dephosphorylates and inactivates ERK, providing a direct example of negative regulation of a hydrolase-dependent kinase cascade. Soluble epoxide hydrolase (EPHX2) activity is modulated in activated astrocytes and influences STAT3-driven immune responses, linking hydrolase regulation to neuroinflammation. Researchers study GO:0051346 to identify druggable checkpoints, to interpret phospho-proteomic and transcriptomic data, and to build causal CRISPR models. The term is not a single pathway but a functional class: any mechanism that lowers hydrolase catalytic rate qualifies, from direct inhibitors to GTPase-activating proteins that accelerate the intrinsic GTP hydrolysis of Ras-family GTPases. This breadth makes GO:0051346 a powerful annotation for systems-level analysis of signaling thresholds and disease mechanisms.
negative regulation of hydrolase activity At A Glance
| GO ID | GO:0051346 |
|---|---|
| GO term | negative regulation of hydrolase activity |
| Ontology | biological_process |
| Definition | Any process that stops or reduces the rate of hydrolase activity, the catalysis of the hydrolysis of various bonds. |
| Synonym | down regulation of hydrolase activity; down-regulation of hydrolase activity; downregulation of hydrolase activity; hydrolase inhibitor; inhibition of hydrolase activity |
| Major function | Sets thresholds and duration of signaling, immune, and metabolic pathways by limiting bond hydrolysis |
| Representative regulators | DUSP3/VHR, TNFAIP3/A20, RASA1, EPHX2, MBTPS1 |
| Disease relevance | Cancer, neuroinflammation, cardiovascular and metabolic disorders |
| Research methods | CRISPR KO/point-mutation/knock-in/overexpression, phospho-proteomics, activity assays, transcriptomics |
What Is GO:0051346?
In plain terms, GO:0051346 describes all the ways a cell slows down or shuts off enzymes that cut chemical bonds using water. The official QuickGO definition is: any process that stops or reduces the rate of hydrolase activity, the catalysis of the hydrolysis of various bonds. Synonyms include down regulation of hydrolase activity, down-regulation of hydrolase activity, downregulation of hydrolase activity, hydrolase inhibitor, and inhibition of hydrolase activity. It is a biological_process term, meaning it describes a coordinated cellular event rather than a physical structure or a single molecular function. Negative regulation can be direct, such as a protein inhibitor binding a protease, or indirect, such as a phosphatase removing an activating phosphate from a hydrolase.
Why Is negative regulation of hydrolase activity Important in Cell Biology?
GO:0051346 is important because hydrolase activity is a terminal, often irreversible step in many pathways, so its negative regulation determines whether a signal is transient or sustained. When this brake fails, pathways such as NF-kB, ERK/MAPK, and eicosanoid signaling become hyperactive, driving inflammation, proliferation, and tissue injury. Conversely, excessive hydrolase inhibition can blunt protective responses, as seen when soluble epoxide hydrolase modulation alters endothelial nitric oxide synthase activation. Understanding GO:0051346 therefore informs drug target selection, biomarker interpretation, and the design of CRISPR models that test causality rather than correlation.
• Controls signaling duration by terminating phosphatase, GTPase, and protease activity.
• Restrains inflammatory NF-kB signaling through A20-dependent mechanisms.
• Modulates neuroinflammatory STAT3 responses via soluble epoxide hydrolase.
• Influences cardiovascular endothelial function and nitric oxide synthase activation.
• Provides druggable checkpoints for cancer and inflammatory disease.
• Explains off-target and feedback effects in kinase/phosphatase inhibitor studies.
• Enables systems-level interpretation of phospho-proteomic datasets.
• Supports CRISPR causality testing of candidate hydrolase regulators.
• Links metabolic lipid signaling to immune cell state.
• Guides design of conditional and tissue-specific disease models.
What Happens During negative regulation of hydrolase activity?
Recognition of the target hydrolase
In simple terms: First, the cell must identify which bond-cutting enzyme to slow down.
Negative regulation begins when a regulator physically or functionally engages a hydrolase. This can involve direct binding by an inhibitor, recruitment of a phosphatase that removes an activating phosphate, or interaction with a scaffold that restricts substrate access. For example, VRK3-mediated activation of the VHR phosphatase leads to ERK dephosphorylation, illustrating how an upstream regulator selects a hydrolase-dependent substrate for inhibition. In the NF-kB system, A20 is recruited to signaling complexes where it restricts upstream hydrolase-dependent events, thereby dampening canonical NF-kB activation.
Direct inhibition or competitive blockade
In simple terms: The regulator blocks the enzyme's active site or competes for its substrate.
Once engaged, negative regulation can be direct. Protein inhibitors may occlude the catalytic site, while decoy substrates or altered substrate availability reduce effective hydrolysis. In Ras signaling, GTPase-activating proteins such as RASA1 accelerate the intrinsic GTP hydrolysis of Ras, converting active GTP-bound Ras to the inactive GDP-bound form and thereby negatively regulating a GTPase hydrolase cycle. This mechanism is structurally well characterized and demonstrates how a regulator can enhance rather than block hydrolysis to achieve negative regulation of downstream activity.
Post-translational modification of the hydrolase
In simple terms: Chemical tags are added or removed to switch the enzyme down.
Phosphorylation, ubiquitination, and related modifications can reduce hydrolase catalytic efficiency or target the enzyme for degradation. The VHR phosphatase provides a clear example: by dephosphorylating ERK, VHR negatively regulates ERK activity, effectively acting as a brake on a kinase cascade that depends on phosphorylation cycles. In immune signaling, A20 combines deubiquitinase and ubiquitin-ligase activities to remodel signaling complexes and terminate NF-kB activation, a process that depends on precise post-translational control.
Spatial sequestration and scaffold control
In simple terms: The enzyme is moved away from its substrate or held in place by scaffolds.
Localization is a major layer of negative regulation. Scaffolds and adaptors can sequester hydrolases in specific compartments, limiting access to substrates. In the Rcs phosphorelay, RcsF-independent mechanisms of signaling within the membrane sensor complex illustrate how spatial organization and protein-protein interactions shape signaling output. Similarly, Ephexin5 regulation of Cdc42 is activity-dependent and controls synapse growth and stabilization, showing that spatial and activity-dependent control of GTPase regulators has direct morphological consequences.
Feedback loops and pathway-level tuning
In simple terms: The cell uses feedback to keep the brake applied only when needed.
Negative regulation of hydrolase activity is often embedded in feedback loops. ERK activation can induce phosphatases that later shut ERK down, creating a negative feedback circuit. In lipid signaling, soluble epoxide hydrolase activity is modulated during astrocyte activation and influences STAT3 activity, linking hydrolase regulation to transcriptional feedback in immune responses. Site-1 protease acts as a negative regulator of sarcolipin promoter activity, demonstrating that proteolytic hydrolases can themselves be regulated to control downstream gene expression.
Key Genes Involved in GO:0051346 negative regulation of hydrolase activity
The following genes and proteins are experimentally documented participants in or regulators of negative regulation of hydrolase activity (GO:0051346).
| Gene | Major Role | Research Relevance |
|---|---|---|
| DUSP3 (VHR) | Phosphatase that dephosphorylates ERK, negatively regulating ERK activity | Model for phosphatase-mediated hydrolase inhibition and MAPK feedback |
| TNFAIP3 (A20) | Negative regulator of canonical NF-kB signaling | Key target in inflammation and B-cell lymphoma research |
| RASA1 | Ras-specific GTPase-activating protein accelerating Ras GTP hydrolysis | Prototype for GAP-mediated negative regulation of GTPase hydrolases |
| EPHX2 | Soluble epoxide hydrolase modulating immune responses and STAT3 activity | Neuroinflammation and lipid signaling model |
| EPHX2 | Phosphatase activity regulating eNOS activation | Cardiovascular endothelial function studies |
| MBTPS1 | Site-1 protease negatively regulating sarcolipin promoter activity | Protease-dependent transcriptional control model |
| CDC42 | GTPase regulated by Ephexin5 in an activity-dependent manner | Synapse growth and cytoskeletal signaling research |
| EPHEXIN5 | Regulator of Cdc42 driving synapse growth and stabilization | Neuronal morphogenesis and synaptic plasticity |
| RCSF | Component of Rcs phosphorelay signaling | Bacterial signaling and membrane sensor studies |
| RCS phosphorelay components | Signal transduction within the Rcs system | Bacterial envelope stress response research |
| VRK3 | Activates VHR phosphatase to negatively regulate ERK | Upstream regulator in MAPK shutdown |
| ERK | Substrate of VHR-mediated negative regulation | Readout for hydrolase-dependent signaling |
| STAT3 | Transcription factor influenced by soluble epoxide hydrolase | Immune and astrocyte activation studies |
| eNOS | Target of soluble epoxide hydrolase phosphatase activity | Endothelial function and cardiovascular research |
| Sarcolipin | Promoter activity negatively regulated by site-1 protease | Muscle calcium handling and thermogenesis |
| NF-kB | Pathway restrained by A20-mediated negative regulation | Inflammation and cancer signaling |
| Ras | GTPase negatively regulated by GAPs such as RASA1 | Oncogenic signaling and drug resistance |
How Is negative regulation of hydrolase activity Regulated?
Negative regulation of hydrolase activity is itself regulated at multiple levels. Upstream kinases and phosphatases control the activation state of hydrolase regulators; for instance, VRK3-mediated activation of VHR is required for ERK dephosphorylation, meaning the brake on ERK depends on a separate regulatory input. Feedback loops are common: ERK activation can induce phosphatases that subsequently limit ERK signaling. In immune signaling, A20 expression and activity are tightly controlled to prevent constitutive NF-kB activation, and loss of this control drives inflammatory pathology. Spatial regulation also matters, as activity-dependent control of Cdc42 by Ephexin5 determines where and when GTPase regulation occurs during synapse growth. In lipid signaling, soluble epoxide hydrolase activity is modulated in activated astrocytes and affects STAT3 activity, linking environmental or inflammatory cues to hydrolase regulation. Finally, proteolytic regulators such as site-1 protease can control transcription of target genes like sarcolipin, adding a transcriptional layer to hydrolase inhibition.
negative regulation of hydrolase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFAIP3 (A20) | NF-kB-driven inflammation and lymphoma | A20 knockout and point-mutation cell lines with NF-kB reporter assays |
| EPHX2 | Neuroinflammation and astrocyte STAT3 activation | Astrocyte overexpression and knockout models with cytokine profiling |
| EPHX2 | Endothelial dysfunction and eNOS regulation | Endothelial cells with EPHX2 point mutations and eNOS activity assays |
| RASA1 | Ras-driven oncogenesis | RASA1 knockout and knock-in models with Ras-GTP pulldown |
| MBTPS1 | Muscle calcium handling and sarcolipin regulation | Site-1 protease knockout with sarcolipin promoter reporter |
Cancer and NF-kB-driven malignancy
Loss of negative regulation of hydrolase activity can unleash constitutive survival and inflammatory signaling. A20 (TNFAIP3) is a critical negative regulator of canonical NF-kB signaling, and its dysfunction is associated with constitutive NF-kB activation that supports tumor cell survival and proliferation. Because A20 acts through ubiquitin-dependent remodeling of signaling complexes, its loss removes a key brake on hydrolase-dependent signaling events. Ras-specific GTPase-activating proteins such as RASA1 provide another example: by accelerating Ras GTP hydrolysis, they negatively regulate Ras output, and disruption of this control contributes to oncogenic signaling.
Neuroinflammation and astrocyte activation
Soluble epoxide hydrolase (EPHX2) modulates immune responses in activated astrocytes and influences STAT3 activity, placing hydrolase regulation at the center of neuroinflammatory signaling. Because STAT3 is a major driver of reactive astrocyte programs, changes in EPHX2 activity can shift the balance between protective and pathological inflammation. This makes GO:0051346 relevant to neurodegenerative and neuroinflammatory disease models where astrocyte state is a key variable.
Cardiovascular and endothelial dysfunction
The phosphatase activity of soluble epoxide hydrolase regulates simvastatin-activated endothelial nitric oxide synthase, linking hydrolase regulation to vascular function and lipid-lowering drug responses. When this regulatory layer is altered, endothelial nitric oxide production can be impaired, contributing to endothelial dysfunction. This illustrates how negative regulation of hydrolase activity can be both a therapeutic target and a modifier of drug response.
Muscle and metabolic control
Site-1 protease acts as a negative regulator of sarcolipin promoter activity, connecting a proteolytic hydrolase to calcium handling and thermogenic gene expression in muscle. Dysregulation of this axis could influence muscle metabolism and stress responses, making it a candidate for metabolic and musculoskeletal disease research. This example broadens GO:0051346 beyond classical signaling into transcriptional and metabolic control.
From negative regulation of hydrolase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase hydrolase activity? | CRISPR knockout cell line with activity assay |
| Does a specific residue control inhibitory function? | Point-mutation knock-in cell line |
| Does a disease variant alter hydrolase regulation? | Knock-in of patient variant with phospho-proteomics |
| Where does the regulator localize? | Tagged knock-in with imaging |
| Does overexpression phenocopy inhibition? | Doxycycline-inducible overexpression line |
| Which pathways depend on the regulator? | CRISPR library screening with transcriptomic readout |
How to Study the negative regulation of hydrolase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-proteomics | Changes in phosphorylation of hydrolase substrates | ERK dephosphorylation after VHR perturbation |
| GTPase activity assay | GTP hydrolysis and Ras-GTP levels | RASA1 GAP function testing |
| Epoxide hydrolase activity assay | EPHX2 catalytic rate | Astrocyte and endothelial cell studies |
| RNA-seq | Transcriptional consequences of hydrolase regulation | NF-kB and STAT3 target profiling |
| Promoter reporter assay | Transcriptional control of target genes | Sarcolipin promoter regulation by site-1 protease |
| Live-cell imaging | Localization and dynamics of regulators | Synapse growth and phosphorelay signaling |
| CRISPR library screening | Gene requirements for a phenotype | Discovery of hydrolase regulators |
| Bioinformatics pathway analysis | GO and pathway enrichment | Prioritizing hits in GO:0051346 |
Phospho-proteomics and activity assays
Because many hydrolase regulators act through phosphorylation, phospho-proteomics is a primary method to detect changes in signaling output after CRISPR perturbation. VHR-mediated ERK dephosphorylation was demonstrated through targeted analysis of ERK phosphorylation status. Activity assays for GTPases, such as Ras-GTP pulldown, directly measure the consequence of GAP-mediated negative regulation. For lipid hydrolases, epoxide hydrolase activity assays can quantify EPHX2 function in cells and tissues.
Transcriptomics and pathway profiling
RNA-seq and pathway enrichment reveal downstream consequences of altered hydrolase regulation. A20-dependent negative regulation of NF-kB can be monitored with NF-kB target gene panels. Soluble epoxide hydrolase modulation of STAT3 activity can be assessed by measuring STAT3 target transcripts in activated astrocytes. Site-1 protease regulation of sarcolipin promoter activity can be studied with promoter-reporter assays coupled to transcript quantification.
Imaging and spatial analysis
Localization of hydrolase regulators determines their function. Activity-dependent regulation of Cdc42 by Ephexin5 was resolved using imaging of synapse growth and stabilization. Bacterial phosphorelay signaling components can be tracked with fluorescent fusions to understand spatial control. Tagged knock-in models enable live-cell imaging of regulator dynamics without overexpression artifacts.
CRISPR screening and bioinformatics
Pooled CRISPR screens can identify genes whose loss changes hydrolase-dependent signaling. Hits are prioritized using pathway databases and GO annotation, including GO:0051346, to distinguish direct regulators from downstream effectors. Bioinformatics integration of phospho-proteomic and transcriptomic data helps build causal networks around hydrolase inhibition.
How CRISPR Can Be Used to Study GO:0051346 negative regulation of hydrolase activity
Knockout
CRISPR knockout is used to remove a candidate hydrolase regulator and test whether hydrolase activity or downstream signaling increases. For example, knocking out TNFAIP3 (A20) is expected to enhance canonical NF-kB signaling, providing a causal test of its negative regulatory role. Knockout of RASA1 would be predicted to elevate Ras-GTP levels, directly probing GAP-mediated negative regulation of Ras. Knockout models are typically validated with activity assays and phospho-proteomics.
Point Mutation
Point-mutation knock-in allows separation of catalytic and scaffolding functions. For a phosphatase such as VHR, mutating the catalytic cysteine can distinguish dephosphorylation-dependent ERK regulation from protein-protein interaction effects. For EPHX2, point mutations affecting phosphatase versus epoxide hydrolase activity can dissect which enzymatic function controls eNOS activation. These models are essential when a protein has multiple enzymatic activities.
Knock-in
Knock-in of disease-associated variants or tagged alleles enables physiologically relevant studies. Tagged knock-in of regulators such as Ephexin5 allows imaging of activity-dependent Cdc42 regulation at synapses without overexpression. Knock-in of patient variants in TNFAIP3 can reveal how specific mutations impair NF-kB negative regulation. Knock-in of RASA1 variants can test effects on Ras-GTP hydrolysis in an endogenous context.
Overexpression
Overexpression models test sufficiency: if a regulator is overexpressed, does it reduce hydrolase activity and downstream signaling? Inducible overexpression of VHR or A20 can suppress ERK or NF-kB output, respectively. Overexpression of soluble epoxide hydrolase can modulate STAT3 activity in astrocytes. These systems are useful for dose-response studies and for validating directionality of regulation.
How EDITGENE Supports negative regulation of hydrolase activity Research
Researchers studying negative regulation of hydrolase activity-related genes often need to determine whether a candidate gene is causally involved in controlling hydrolase output, or whether observed changes are secondary. CRISPR-based cell models provide the cleanest way to establish causality, and EDITGENE supports this workflow from design to validation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of hydrolase activity research.
Frequently Asked Questions About negative regulation of hydrolase activity
What is GO:0051346?
GO:0051346 is the Gene Ontology biological process term negative regulation of hydrolase activity, defined as any process that stops or reduces the rate of hydrolase activity, the catalysis of the hydrolysis of various bonds.
What does negative regulation of hydrolase activity mean in simple terms?
It means the cell is slowing down or switching off enzymes that cut chemical bonds using water, such as phosphatases, GTPases, proteases, and epoxide hydrolases.
What genes are involved in negative regulation of hydrolase activity?
Documented examples include DUSP3/VHR, TNFAIP3/A20, RASA1, EPHX2, MBTPS1, and regulators such as Ephexin5 and VRK3.
How does A20 negatively regulate hydrolase activity?
A20 (TNFAIP3) restrains canonical NF-kB signaling by remodeling signaling complexes, thereby limiting hydrolase-dependent activation events.
How is ERK activity negatively regulated by phosphatases?
VRK3-mediated activation of the VHR phosphatase leads to ERK dephosphorylation, which reduces ERK activity.
What role do GTPase-activating proteins play in GO:0051346?
GTPase-activating proteins such as RASA1 accelerate Ras GTP hydrolysis, converting Ras to its inactive form and negatively regulating downstream signaling.
Is soluble epoxide hydrolase involved in neuroinflammation?
Yes, soluble epoxide hydrolase modulates immune responses in activated astrocytes and influences STAT3 activity.
How can CRISPR be used to study negative regulation of hydrolase activity?
CRISPR knockout, point-mutation, knock-in, and overexpression models can test whether a candidate regulator causally changes hydrolase activity and downstream signaling.
What methods measure negative regulation of hydrolase activity?
Phospho-proteomics, GTPase and epoxide hydrolase activity assays, RNA-seq, promoter reporters, imaging, and CRISPR screens are commonly used.
Why is GO:0051346 important for disease research?
Because loss of hydrolase inhibition can drive cancer, neuroinflammation, and cardiovascular dysfunction, making these regulators therapeutic targets.
Conclusion
GO:0051346, negative regulation of hydrolase activity, captures a fundamental control layer that determines the duration and intensity of signaling, immune, and metabolic responses. From VHR-mediated ERK dephosphorylation to A20-dependent restraint of NF-kB and GAP-accelerated Ras GTP hydrolysis, the mechanisms are experimentally well defined and disease-relevant. CRISPR-based cell models now make it possible to move from correlation to causation for any candidate regulator within this term. By combining knockout, point-mutation, knock-in, overexpression, and library screening with phospho-proteomic and transcriptomic readouts, researchers can map the hydrolase inhibitory network and identify new therapeutic opportunities.
References
- 1. Petshow S et al.. 2025. Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization.. Sci Adv 11(13):eadp5782 PMID: 40138406
- 2. Kang TH et al.. 2006. Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase.. Nat Cell Biol 8(8):863-9 PMID: 16845380
- 3. Hung CC et al.. 2019. Soluble epoxide hydrolase modulates immune responses in activated astrocytes involving regulation of STAT3 activity.. J Neuroinflammation 16(1):123 PMID: 31176371
- 4. Petchiappan A et al.. 2024. RcsF-independent mechanisms of signaling within the Rcs phosphorelay.. PLoS Genet 20(12):e1011408 PMID: 39724052
- 5. Sharma I et al.. 2025. Site-1 protease is a negative regulator of sarcolipin promoter activity.. Commun Biol 8(1):1351 PMID: 40993245
- 6. Pujari R et al.. 2013. A20-mediated negative regulation of canonical NF-κB signaling pathway.. Immunol Res 57(1-3):166-71 PMID: 24242761
- 7. Scheffzek K et al.. 2019. Ras-Specific GTPase-Activating Proteins-Structures, Mechanisms, and Interactions.. Cold Spring Harb Perspect Med 9(3) PMID: 30104198
- 8. Hou HH et al.. 2015. Role of phosphatase activity of soluble epoxide hydrolase in regulating simvastatin-activated endothelial nitric oxide synthase.. Sci Rep 5:13524 PMID: 26304753
